Company intelligence / Profile preview

TET Systems

Heidelberg, Germany

Ownership: Private
Development stage: Other

Overview

TET Systems is a privately held German biotech company specializing in intellectual property licensing for its proprietary Tet Technology. This platform, invented by Prof. Dr. Hermann Bujard and colleagues, is the most widely used method for controlling gene expression in eukaryotic cells, offering tight and reversible regulation. It has broad applications in basic research, drug discovery, manufacturing, and gene therapy, and has been cited in over 20,000 scientific publications.

Modalities: Gene therapy
Industry: Non-Drug Biotech

Partnerships

Clontech Laboratories (now part of Takara Bio)RIKEN BioResource CenterCharles RiverGenOwayTaconic BiosciencesVarious academic institutionsBiospecimen Laboratories (marketing partner in Japan as of July 2024)

Beyond the preview

Go deeper on TET Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TET Systems.

Explore the full profile